SCYNEXIS Is Recalling BREXAFEMME And Temporarily Halting Clinical Studies Of Ibrexafungerp Due To The Risk Of Cross Contamination With A Non-Antibacterial Beta-Lactam Drug Substance During The Manufacturing Process
Portfolio Pulse from Benzinga Newsdesk
SCYNEXIS has announced a recall of BREXAFEMME and a temporary halt to clinical studies of ibrexafungerp due to the risk of cross contamination with a non-antibacterial beta-lactam drug substance during manufacturing, according to an SEC filing.
September 25, 2023 | 1:08 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
The recall of BREXAFEMME and halt of ibrexafungerp studies by SCYNEXIS may negatively impact the company's stock in the short term.
The recall of a product and halt of clinical studies can lead to financial losses and reputational damage, which can negatively impact the company's stock price. The news is directly related to SCYNEXIS and is of high importance to its investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100